Russel-Jones D, Vaag A, Schmitz O, et al
Pharmaceutical GLP-1 receptor agonists are engineered to resist DPP-4 degradation, extending their half-life dramatically
If orforglipron receives a more favorable formulary position than competing injectables (due to lower list price, manufacturing scalability, or negotiated rebates), payers may require a trial of orforglipron before approving more expensive injectable alternatives
Suravajjala S, Cohenford M, Frost LR, Pampati PK, Dain JA
Extreme neuroplasticity of Hippocampal CA1 pyramidal neurons in hibernating mammalian species
Some patients report that morning injections increase nausea during lunch when they are at work or away from home, making it less convenient to manage side effects in professional settings